PESG Releases Report on Nuvectis Pharma: With Summit Therapeutics Threatening to Dethrone Merck's Keytruda, Nuvectis' NXP900 is One to Watch
Nuvectis Pharma, Inc. (NVCT)
Company Research
Source: Business Wire
With its focus on targeting well-defined subgroups by inhibiting SRC/YES1 kinases in Non Small-Cell Lung Cancer patients resistant to EGFR and ALK targeted therapies, Nuvectis Pharma’s NXP900 could hold similar transformative potential in NSCLC as Summit Therapeutics’s IvonescimabThe Bottom LineSummit Therapeutics (NASDAQ: SMMT) recently reported Ivonescimab’s Phase 3 results from study conducted in China that showed significant efficacy in addressing NSCLC treatment resistance, surpassing Merck's Keytruda in key outcomes and sending SMMT stock skyrocketing.Like Ivonescimab, Nuvectis Pharma’s (NASDAQ: NVCT) NXP900 tackles resistance in NSCLC but targets a different pathway by inhibiting SRC/YES1 kinases, which are key drivers of cancer survival. Both drugs focus on well-defined subgroups from the outset—Ivonescimab targets patients with PD-L1 expression, while NXP900 focuses on subgroups with EGFR and ALK mutations—ensuring targeted treatment for specific patient populations. Each one
Show less
Read more
Impact Snapshot
Event Time:
NVCT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVCT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVCT alerts
High impacting Nuvectis Pharma, Inc. news events
Weekly update
A roundup of the hottest topics
NVCT
News
- Nuvectis Pharma CEO Says Increased Dose Intensity Needed To Drive More Efficacy From Ovarian Cancer Lead Drug [Yahoo! Finance]Yahoo! Finance
- Nuvectis Pharma Reports Encouraging NXP800 Interim Data Supporting Ongoing Enrollment in Phase 1b Study in Patients with Platinum-Resistant ARID1a-Mutated Ovarian Cancer [Yahoo! Finance]Yahoo! Finance
- Nuvectis Pharma Reports Encouraging NXP800 Interim Data Supporting Ongoing Enrollment in Phase 1b Study in Patients with Platinum-Resistant ARID1a-Mutated Ovarian CancerGlobeNewswire
- Nuvectis Pharma GAAP EPS of -$0.24 beats by $0.01 [Seeking Alpha]Seeking Alpha
- Nuvectis Pharma, Inc. Reports Third Quarter 2024 Financial Results and Business HighlightsGlobeNewswire
NVCT
Earnings
- 5/7/24 - Beat
NVCT
Sec Filings
- 11/20/24 - Form 4
- 11/18/24 - Form 4
- 11/8/24 - Form 4
- NVCT's page on the SEC website